[Measles cellular immunity in patients with multiple sclerosis]. 1980

S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn

The micromethod of leukocyte migration inhibition test was used to study cellular immunity in patients with multiple sclerosis (MS) to measles virus antigens and some other infectious (vaccinia virus, tuberculin) and noninfectious (brain white matter extract) antigens. In MS patients the reaction to measles antigen was weaker than in the control group, while the reactivity to the brain white matter extract was increased. As for the responses to vaccinia virus and tuberculin, these two grous did not differ statistically. The population of MS patients under study was not homogeneous in the intensity of measles cellular immunity (MCI). In the early stages of multiple sclerosis, MCI indices did not differ from those in the control group. MCI was the weakest in those subjects developing MS early in life who showed rapid worsening of the clinical status. Besides, MCI values were age-related: in older age groups they were low both in MS patients and in control subjects.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007961 Leukocyte Migration-Inhibitory Factors Protein factor(s) released by sensitized lymphocytes (and possibly other cells) that inhibit the movement of LEUKOCYTES, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the LEUKOCYTE MIGRATION CAPILLARY TUBE TECHNIQUE (LMCT) and the LEUKOCYTE MIGRATION AGAROSE TEST (LMAT). Migration-Inhibition Factors, Leukocyte,Leukocyte Migration-Inhibition Factors,Migration-Inhibitory Factors, Leukocyte,Factors, Leukocyte Migration-Inhibition,Factors, Leukocyte Migration-Inhibitory,Leukocyte Migration Inhibition Factors,Leukocyte Migration Inhibitory Factors,Migration Inhibition Factors, Leukocyte,Migration Inhibitory Factors, Leukocyte
D008297 Male Males
D008459 Measles virus The type species of MORBILLIVIRUS and the cause of the highly infectious human disease MEASLES, which affects mostly children. Edmonston virus
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
November 1973, Lancet (London, England),
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
January 1992, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
January 1977, British medical bulletin,
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
January 1977, Acta neurologica Scandinavica. Supplementum,
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
January 1981, Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove,
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
December 1973, The Journal of experimental medicine,
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
April 1975, Lancet (London, England),
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
February 1976, Lancet (London, England),
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
July 1967, Neurology,
S N Atanadze, and G Kh Kodkind, and Smirnov YuK, and V Ia Khomak, and A M Veĭn
April 1964, Archives of neurology,
Copied contents to your clipboard!